Gerard Sanacora, MD, PhD

ECT: a gold-standard treatment for major depressive disorder. Ketamine/esketamine: a newer therapeutic option. This ACNP 2023 Annual Meeting session took a deeper look.

What is the most abundant and ubiquitous neurotransmitter in the mammalian central nervous system?

Dr Sanacora discusses the new indication for esketamine, SPRAVATO®, and how it might be used to treat patients with Major Depressive Disorder with acute risk of suicide ideation.

The lay press has focused a lot of attention on the use of ketamine as a potentially rapidly acting treatment for depression. But are psychiatrists really ready to offer ketamine as a treatment alternative for mood disorders? An expert weighs in.

Dr Gerard Sanacora discusses novel antidepressant agents with potential clinical relevance for the treatment of major depressive disorder and bipolar disorder.

New treatment options for mood disorders are under investigation, including the novel class of glutamatergic drugs.

A novel class of drugs directly targets the glutamatergic neurotransmitter system and produces rapid antidepressant effects in some patients.

There is rapidly escalating interest in drugs that target the glutamatergic neurotransmitter system, especially NMDA receptor modulators. The hope is that they will fill the large unmet need for rapid-acting antidepressant medications with efficacy in treatment-resistant depression.